Altimmune (ALT) Non-Current Deferred Tax Liability (2017 - 2019)
Altimmune (ALT) posted quarterly Non-Current Deferred Tax Liability of $58500.0 for Q2 2019, down 98.68% year-over-year from $4.4 million in Q2 2018, and little changed quarter-over-quarter from $58500.0 in Q1 2019.
Altimmune (ALT) Non-Current Deferred Tax Liability (2017 - 2019) Analysis & Trends
Altimmune (ALT) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $58500.0 the latest figure, recorded in Q2 2019.
- In Q2 2019, Non-Current Deferred Tax Liability fell 98.68% year-over-year to $58500.0; the TTM figure through Jun 2019 stood at $58500.0 (down 98.68% YoY), while the FY2018 annual figure was $58500.0, down 99.01% from the prior year.
- Non-Current Deferred Tax Liability held at $58500.0 in Q2 2019 per ALT's latest filing, from $58500.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $8.5 million in Q2 2017 and bottomed at $58500.0 in Q4 2018.
- Historically, Non-Current Deferred Tax Liability has averaged $4.0 million across 3 years, with a median of $4.4 million in 2018.
- On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 48.14% in 2018 and fell as far as 99.01% in 2018.
- Altimmune's Non-Current Deferred Tax Liability stood at $5.9 million in 2017, then plunged by 99.01% to $58500.0 in 2018, then changed by 0.0% to $58500.0 in 2019.
- Business Quant data shows ALT's Non-Current Deferred Tax Liability at $58500.0 in Q2 2019, $58500.0 in Q1 2019, and $58500.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 58,500.00 |
| Jun 30, 2019 | 58,500.00 |
| Mar 31, 2019 | 58,500.00 |
| Mar 31, 2019 | 58,500.00 |
| Dec 31, 2018 | 58,500.00 |
| Dec 31, 2018 | 58,500.00 |
| Sep 30, 2018 | 2.89 Mn |
| Sep 30, 2018 | 2.89 Mn |
| Jun 30, 2018 | 4.43 Mn |
| Jun 30, 2018 | 4.43 Mn |
| Mar 31, 2018 | 5.44 Mn |
| Mar 31, 2018 | 5.44 Mn |
| Dec 31, 2017 | 5.94 Mn |
| Dec 31, 2017 | 5.94 Mn |
| Sep 30, 2017 | 8.31 Mn |
| Sep 30, 2017 | 8.31 Mn |
| Jun 30, 2017 | 8.54 Mn |
| Jun 30, 2017 | 8.54 Mn |